609TiPIntermittent or continuous panitumumab (PAN) plus FOLFIRI for first-line treatment of patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC): A randomized phase II trial (IMPROVE). (23rd October 2018) - De Stefano, A; Nasti, G; Febbraro, A; Rosati, G; Giuliani, F; Santini, D; Aprile, G; Scartozzi, M; Silvestris, F; Luppi, G; Lolli, I; Mastroianni, C; et al.